Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Egorov A, Liu Y, Cathcart J, Bako E, Tecson K, Verma S, Cortés J.
Hurvitz SA, et al. Among authors: tecson k.
ESMO Open. 2024 May;9(5):102924. doi: 10.1016/j.esmoop.2024.102924. Epub 2024 Apr 24.
ESMO Open. 2024.
PMID: 38796287
Free PMC article.
Clinical Trial.